Highly potent synthetic polyamides, bisdistamycins, and lexitropsins as inhibitors of human immunodeficiency virus type 1 integrase

被引:63
作者
Neamati, N
Mazumder, A
Sunder, S
Owen, JM
Tandon, M
Lown, JW
Pommier, Y
机构
[1] NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA
[2] Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada
关键词
D O I
10.1124/mol.54.2.280
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Alignment of the available human immunodeficiency virus type 1 (HIV-1) viral DNA termini [U5 and U3 long terminal repeats (LTRs)] shows a high degree of conservation and the presence of a stretch of five or six consecutive adenine and thymine (AT) sequences similar to 10 nucleotides away from each LTR end. A series of AT-selective minor-groove binders, including distamycin and bisdistamycins, bisnetropsins, novel lexitropsins, and the classic monomeric DNA binders Hoechst 33258, 4'-diamino-2-phenylindole, pentamidine, berenil, spermine, and spermidine, were tested for their inhibitory activities against HIV-1 integrase (IN). Although netropsin, distamycin, and all other monomeric DNA binders showed weak activities in the range of 50-200 mu M, some of the polyamides, bisdistamycins, and lexitropsins were remarkably active at nanomolar concentrations. Bisdistamycins were 200 times less potent when the conserved AAAAT stretch present in the U5 LTR was replaced with GGGGG, consistent with the preferred binding of these drugs to AT sequences. DNase I footprinting of the U5 LTR further demonstrated the selectivity of these bisdistamycins for the conserved AT sequence. The tested compounds were more potent in Mg+2 than in Mn+2 and inhibited IN50-212 deletion mutant in disintegration assays and the formation of IN/DNA complexes. The lexitropsins also were active against HIV-2 IN. Some of the synthetic polyamides exhibited significant antiviral activity. Taken together, these data suggest that selective targeting of the U5 and U3 ends of the HIV-1 LTRs can inhibit IN function. Polyamides might represent new leads for the development of antiviral agents against acquired immune deficiency syndrome.
引用
收藏
页码:280 / 290
页数:11
相关论文
共 40 条
[1]   Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription [J].
Arts, EJ ;
Wainberg, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :527-540
[2]   Alternate strand DNA triple helix-mediated inhibition of HIV-1 U5 long terminal repeat integration in vitro [J].
Bouziane, M ;
Cherny, DI ;
Mouscadet, JF ;
Auclair, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (17) :10359-10364
[3]   DOMAINS OF THE INTEGRASE PROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RESPONSIBLE FOR POLYNUCLEOTIDYL TRANSFER AND ZINC-BINDING [J].
BUSHMAN, FD ;
ENGELMAN, A ;
PALMER, I ;
WINGFIELD, P ;
CRAIGIE, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3428-3432
[4]   EFFECT OF TOPOISOMERASE INHIBITORS ON THE INVITRO HIV DNA INTEGRATION REACTION [J].
CARTEAU, S ;
MOUSCADET, JF ;
GOULAOUIC, H ;
SUBRA, F ;
AUCLAIR, C .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 192 (03) :1409-1414
[5]   REVERSAL OF INTEGRATION AND DNA SPLICING MEDIATED BY INTEGRASE OF HUMAN-IMMUNODEFICIENCY-VIRUS [J].
CHOW, SA ;
VINCENT, KA ;
ELLISON, V ;
BROWN, PO .
SCIENCE, 1992, 255 (5045) :723-726
[6]   TOWARD IMPROVED ANTI-HIV CHEMOTHERAPY - THERAPEUTIC STRATEGIES FOR INTERVENTION WITH HIV-INFECTIONS [J].
DECLERCQ, E .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (14) :2491-2517
[7]  
DeClercq E, 1996, MED RES REV, V16, P125, DOI 10.1002/(SICI)1098-1128(199603)16:2<125::AID-MED1>3.0.CO
[8]  
2-2
[9]   EFFICIENT MAGNESIUM-DEPENDENT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INTEGRASE ACTIVITY [J].
ENGELMAN, A ;
CRAIGIE, R .
JOURNAL OF VIROLOGY, 1995, 69 (09) :5908-5911
[10]   HIV-1 DNA INTEGRATION - MECHANISM OF VIRAL-DNA CLEAVAGE AND DNA STRAND TRANSFER [J].
ENGELMAN, A ;
MIZUUCHI, K ;
CRAIGIE, R .
CELL, 1991, 67 (06) :1211-1221